(Q50979000)

English

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

scientific article published in January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

12

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Andrea Mancuso

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Eugenio Donato Di Paola

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alfonso Catalano

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Linda Cerbone

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Andrea Zivi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Carlo Messina

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Silvia Alonso

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Leonardo Vigna

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Rita Caristo

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

109

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

200-206

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Targeting Raf-kinase: molecular rationales and translational issues.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10421.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2011.10421.X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50979000&oldid=2186353263"